Lead Product(s): ChAd3-SUDV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Deal Size: $215.5 million Upfront Cash: Undisclosed
Deal Type: Funding May 13, 2020
This new funding from BARDA will enable Sabin and ReiThera to advance the investigational Ebola Sudan and Marburg vaccines through GMP manufacturing and release of ChAd3-MARV and ChAd3-SUDV Phase 2 clinical trial.